S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths

DexCom Stock Price, News & Analysis (NASDAQ:DXCM)

$116.97
-1.92 (-1.61%)
(As of 12/8/2023 ET)
Compare
Today's Range
$116.92
$119.39
50-Day Range
$75.49
$118.89
52-Week Range
$74.75
$139.55
Volume
2.38 million shs
Average Volume
3.68 million shs
Market Capitalization
$45.19 billion
P/E Ratio
128.54
Dividend Yield
N/A
Price Target
$132.33

DexCom MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
13.1% Upside
$132.33 Price Target
Short Interest
Healthy
4.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.88mentions of DexCom in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$1.20 M Sold Last Quarter
Proj. Earnings Growth
18.06%
From $1.44 to $1.70 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.96 out of 5 stars

Medical Sector

28th out of 932 stocks

Surgical & Medical Instruments Industry

8th out of 93 stocks


DXCM stock logo

About DexCom Stock (NASDAQ:DXCM)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DXCM Stock Price History

DXCM Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
DexCom (NASDAQ:DXCM) PT Raised to $122.00 at Morgan Stanley
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
11 Best Long Term Growth Stocks To Invest In
DexCom Stock (NASDAQ:DXCM) Insider Trades
DexCom (DXCM) is an Incredible Growth Stock: 3 Reasons Why
2 Stock Split Growth Stocks to Buy and Hold
Dexcom Rings the Opening Bell
See More Headlines
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/26/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/08/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:DXCM
CUSIP
25213110
Employees
7,600
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$132.33
High Stock Price Target
$160.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+13.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
15 Analysts

Profitability

Net Income
$341.20 million
Pretax Margin
17.56%

Debt

Sales & Book Value

Annual Sales
$2.91 billion
Cash Flow
$1.29 per share
Book Value
$5.52 per share

Miscellaneous

Free Float
384,790,000
Market Cap
$45.19 billion
Optionable
Optionable
Beta
1.22

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of DexCom was last updated on Tuesday, November 28, 2023 at 10:07 AM.

Pros

Here are some ways that investors could benefit from investing in DexCom, Inc.:

  • DexCom, Inc. specializes in the design, development, and commercialization of continuous glucose monitoring (CGM) systems. With the increasing prevalence of diabetes, there is a growing demand for CGM systems to help patients manage their blood sugar levels.
  • DexCom's products, such as the Dexcom G6 and Dexcom G7, offer real-time, continuous data on glucose levels, providing valuable insights for diabetes management.
  • The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. This partnership could lead to innovative advancements in CGM technology.
  • DexCom's Dexcom Real-Time API enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices. This opens up opportunities for partnerships and integrations with other healthcare technology companies.
  • Investors may find the current stock price of DexCom, Inc. attractive. Please note that the stock price is subject to market fluctuations and should be evaluated based on recent periods.

Cons

Investors should be bearish about investing in DexCom, Inc. for these reasons:

  • The surgical and medical instruments industry, in which DexCom operates, can be highly competitive. The company may face challenges from existing competitors or new entrants in the market.
  • While DexCom's CGM systems offer valuable data for diabetes management, the adoption of these systems may vary among healthcare providers and individuals with diabetes. Market acceptance and penetration could impact the company's growth potential.
  • As with any medical device company, DexCom is subject to regulatory approvals and compliance. Changes in regulations or delays in obtaining approvals could affect the company's ability to bring new products to market.
  • Investors should consider the financial performance and stability of DexCom, Inc. before making investment decisions. It is important to analyze the company's revenue growth, profitability, and cash flow to assess its long-term sustainability.
  • Market conditions and macroeconomic factors can also impact the performance of DexCom, Inc. Investors should stay informed about industry trends, healthcare policies, and economic indicators that may affect the company's prospects.














DXCM Stock Analysis - Frequently Asked Questions

Should I buy or sell DexCom stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings
or view top-rated stocks.

What is DexCom's stock price target for 2024?

15 brokers have issued 12 month price targets for DexCom's shares. Their DXCM share price targets range from $100.00 to $160.00. On average, they predict the company's stock price to reach $132.33 in the next year. This suggests a possible upside of 13.1% from the stock's current price.
View analysts price targets for DXCM
or view top-rated stocks among Wall Street analysts.

How have DXCM shares performed in 2023?

DexCom's stock was trading at $113.24 at the start of the year. Since then, DXCM stock has increased by 3.3% and is now trading at $116.97.
View the best growth stocks for 2023 here
.

Are investors shorting DexCom?

DexCom saw a decline in short interest in November. As of November 15th, there was short interest totaling 17,750,000 shares, a decline of 15.7% from the October 31st total of 21,060,000 shares. Based on an average daily trading volume, of 5,150,000 shares, the short-interest ratio is currently 3.4 days.
View DexCom's Short Interest
.

When is DexCom's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our DXCM earnings forecast
.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Thursday, October, 26th. The medical device company reported $0.50 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.16. The medical device company earned $975 million during the quarter, compared to analyst estimates of $939.64 million. DexCom had a net margin of 11.08% and a trailing twelve-month return on equity of 25.05%. DexCom's quarterly revenue was up 26.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.28 EPS.
Read the conference call transcript
.

When did DexCom's stock split?

DexCom's stock split on the morning of Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were issued to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom updated its FY 2023 earnings guidance on Friday, September, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.55 billion, compared to the consensus revenue estimate of $3.54 billion.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

Who are DexCom's major shareholders?

DexCom's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (4.32%), Sands Capital Management LLC (3.54%), Blair William & Co. IL (1.17%), Jennison Associates LLC (1.11%), Northern Trust Corp (1.01%) and Clearbridge Investments LLC (0.84%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends
.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does DexCom have any subsidiaries?
The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.
Read More
This page (NASDAQ:DXCM) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -